Nasdaq · Healthcare
Jazz Pharmaceuticals plc (JAZZ)
As-reported financials and recent SEC filings for Jazz Pharmaceuticals plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.27B
Net income
$-356.1M
Net margin
-8.3%
Diluted EPS
$-5.84
ROE
-8.2%
P/E (TTM)
1916.8×
Market cap
$14.45B
Debt / equity
1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Gross profit | — | — | — | — | — |
| Operating income | $-430.2M | $716.6M | $578.6M | $-65.5M | $170.3M |
| Net income | $-356.1M | $560.1M | $414.8M | $-224.1M | $-329.7M |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-10
View on EDGAR →ARS2026-06-08
View on EDGAR →DEFA14A2026-06-08
View on EDGAR →DEF 14A2026-06-08
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on JAZZ
Search Jazz Pharmaceuticals plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.